Neil J. Weiner, Jeffrey W. Goodman, Paul L. Kimmel 

Slides:



Advertisements
Similar presentations
Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral.
Advertisements

A.M. Thompson, T.G. Pickering  Kidney International 
MariLia Bahiense Oliveira, Joao Egidio Romao, Roberto Zatz 
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
End-stage renal disease in developing countries
Volume 83, Issue 3, Pages (March 2013)
End-stage renal disease prevention strategies in Latin America
Volume 63, Issue 6, Pages (June 2003)
Volume 67, Issue 4, Pages (April 2005)
Naïve and central memory T-cell lymphopenia in end-stage renal disease
Volume 86, Issue 6, Pages (December 2014)
Kidney transplantation in a low-resource setting: Nigeria experience
Innate immunity as a driving force in renal disease
Volume 75, Issue 11, Pages (June 2009)
Mortality caused by sepsis in patients with end-stage renal disease compared with the general population  Mark J. Sarnak, Bertrand L. Jaber  Kidney International 
G protein β3 subunit C825T polymorphism in primary IgA nephropathy
Volume 64, Issue 3, Pages (September 2003)
Burden of chronic kidney disease: North Africa
ئەيدىز كېسىلى (AIDS) مەمەتئىمىن دوكتۇر.
Francesco Paolo Schena  Kidney International 
Volume 85, Issue 3, Pages (March 2014)
Volume 84, Issue 2, Pages (August 2013)
End-stage renal disease in living kidney donors
Volume 72, Issue 9, Pages (November 2007)
Comorbidity and confounding in end-stage renal disease
Early mortality in dialysis and adequacy of predialysis renal care: the picture is more complex than we thought  Nicolas Rognant, Maurice Laville  Kidney.
Punit Yadav, Nelson Leung, Paul W. Sanders, Paul Cockwell 
Volume 68, Issue 1, Pages (July 2005)
Volume 70, Issue 11, Pages (December 2006)
Volume 71, Issue 6, Pages (March 2007)
Volume 70, Issue 12, Pages (December 2006)
Volume 75, Issue 1, Pages (January 2009)
Blood pressure targets in hemodialysis patients
Immunologic function and survival in hemodialysis patients
Volume 65, Issue 6, Pages (June 2004)
Volume 76, Issue 5, Pages (September 2009)
American Journal of Kidney Diseases
Adenosine A2A agonists as therapy for glomerulonephritis
Elevated risk of stroke among patients with end-stage renal disease
Alternate-day dialysis may be needed for hemodialysis patients
Racial disparities in access to transplantation: a tough nut to crack
Atrial fibrillation in end-stage renal disease: an emerging problem
V.R. Sørensen, P.M. Hansen, J. Heaf, B. Feldt-Rasmussen 
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease  S. Susan Hedayati, Venkata Yalamanchili,
Volume 69, Issue 8, Pages (April 2006)
E.A. Friedman, A.L. Friedman, P. Eggers  Kidney International 
Serum cystatin C-immunoglobulin high-molecular-weight complexes in kidney and liver transplant patients  Jesús Hermida, Rafael Romero, J. Carlos Tutor 
Peritoneal dialysis in Mexico
Current status of maintenance hemodialysis in Beijing, China
The Iranian model of living renal transplantation
Molecular mechanisms of renal hypertrophy: Role of p27Kip1
Elevated plasma F2-isoprostanes in patients on long-term hemodialysis
Volume 80, Issue 10, Pages (November 2011)
Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral.
Treatment of the primary hyperoxalurias: A new chapter
Charles A. Herzog  Kidney International 
Is complement a target for therapy in renal disease?
Volume 70, Issue 3, Pages (August 2006)
Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular.
Renal replacement therapy in Latin America
Volume 75, Issue 7, Pages (April 2009)
Membranous nephropathy: recent travels and new roads ahead
T cells and T-cell receptors in acute renal failure
Volume 70, Issue 10, Pages (November 2006)
A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan  Yi-Chun.
Volume 80, Issue 9, Pages (November 2011)
IgA nephropathy: Immune mechanisms beyond IgA mesangial deposition
Stephen Pastan, J. Michael Soucie, William M. McClellan 
Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies  Lei-Shi Li, Zhi-Hong Liu  Kidney International 
Presentation transcript:

The HIV-associated renal diseases: Current insight into pathogenesis and treatment  Neil J. Weiner, Jeffrey W. Goodman, Paul L. Kimmel  Kidney International  Volume 63, Issue 5, Pages 1618-1631 (May 2003) DOI: 10.1046/j.1523-1755.2003.00901.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Human immunodeficiency virus (HIV)-associated immune complex-mediated renal disease (HIV-ICD). Primary HIV-1 infection in patients with specific genetic susceptibilities leads to synthesis of HIV-1 proteins. HIV-1 directly infects renal cells and HIV proteins and peptides (some of which are illustrated in the diagram as examples) may stimulate local cellular immune responses. Alternatively, circulating immunoglobulins (IgG, IgM, IgA) may react with HIV-1 proteins, forming circulating immune complexes (CICs), which deposit in renal tissue. A cellular immune response, potentially influenced by host genetic factors, may lead to production of cytokines, growth factors, chemokines, and adhesion molecules. Such a response may lead to various combinations of inflammatory, sclerotic/fibrotic, and apoptotic responses [see text for details]. Kidney International 2003 63, 1618-1631DOI: (10.1046/j.1523-1755.2003.00901.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Percentage of hemodialysis patients with human immunodeficiency virus (HIV) infection in the United States, 1985 to 2000. Data used with permission from the Centers for Disease Control and Prevention, Atlanta, GA, USA and Seminars in Dialysis122. Kidney International 2003 63, 1618-1631DOI: (10.1046/j.1523-1755.2003.00901.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 Incidence of acquired immunodeficiency syndrome (AIDS) nephropathy as a primary diagnosis in end-stage renal disease (ESRD) patients in the United States, 1990 to 1999. Data from the United States Renal Data System28. Kidney International 2003 63, 1618-1631DOI: (10.1046/j.1523-1755.2003.00901.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 4 Incidence (%) of acquired immunodeficiency syndrome (AIDS) nephropathy as a primary diagnosis in end-stage renal disease (ESRD) patients in the United States, 1990 to 1999. Data from the United States Renal Data System28. Kidney International 2003 63, 1618-1631DOI: (10.1046/j.1523-1755.2003.00901.x) Copyright © 2003 International Society of Nephrology Terms and Conditions